Repository logo
 

Optimized inducible shRNA and CRISPR/Cas9 platforms for $\textit{in vitro}$ studies of human development using hPSCs

Published version
Peer-reviewed

Change log

Authors

Bertero, A 
Pawlowski, M 
Ortmann, D 
Snijders, K 
Yiangou, L 

Abstract

Inducible loss of gene function experiments are necessary to uncover mechanisms underlying development, physiology and disease. However, current methods are complex, lack robustness and do not work in multiple cell types. Here we address these limitations by developing single-step optimized inducible gene knockdown or knockout (sOPTiKD or sOPTiKO) platforms. These are based on genetic engineering of human genomic safe harbors combined with an improved tetracycline-inducible system and CRISPR/Cas9 technology. We exemplify the efficacy of these methods in human pluripotent stem cells (hPSCs), and show that generation of sOPTiKD/KO hPSCs is simple, rapid and allows tightly controlled individual or multiplexed gene knockdown or knockout in hPSCs and in a wide variety of differentiated cells. Finally, we illustrate the general applicability of this approach by investigating the function of transcription factors (OCT4 and T), cell cycle regulators (cyclin D family members) and epigenetic modifiers (DPY30). Overall, sOPTiKD and sOPTiKO provide a unique opportunity for functional analyses in multiple cell types relevant for the study of human development.

Description

Keywords

human pluripotent stem cells, shRNA, CRISPR/Cas9, OCT4, POU5F1, T, brachyury, DPY30

Journal Title

Development

Conference Name

Journal ISSN

0950-1991
1477-9129

Volume Title

143

Publisher

The Company of Biologists Ltd
Sponsorship
European Research Council (281335)
European Commission (278955)
Qatar Foundation for Education, Science and Community Development (unknown)
British Council in Israel (52BX14MKSR)
Wings for Life Spinal Cord Research Foundation (WFL-UK-005/11)
Medical Research Council (MR/L016761/1)
Medical Research Council (MC_PC_12009)
British Heart Foundation (None)
This work was supported by a European Research Council starting grant Relieve IMDs (281335 to L.V., D.O., N.R.F.H., M.C.F.Z., E.G.); the Cambridge University Hospitals National Institute for Health Research Biomedical Research Center (L.V., N.R.F.H., F.Sa.); the EU Seventh Framework Programme TISSUGEN (278955 to M.C.d.B.); the Wellcome Trust PhD program (PSAG/048 to L.Y.); a British Heart Foundation PhD Studentship (FS/11/77/39327 to A.B.); a research fellowship from the Deutsche Forschungsgemeinschaft [PA 2369/1-1 to M.P.]; and a core support grant from the Wellcome Trust and Medical Research Council to the Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute (PSAG028). Deposited in PMC for immediate release.